Karyopharm Therapeutics

253 articles with Karyopharm Therapeutics

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021

  8/2/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharm's common stock to 11 newly-hired employees, with a grant date of July 30, 2021.

• Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021

  7/29/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.

• Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

  7/28/2021

  Karyopharm Therapeutics Inc. announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021

  7/1/2021

  Karyopharm Therapeutics Inc. announced that in connection with the hiring of Ms. Sohanya Cheng, Senior Vice President, Sales and Commercial Operations, the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 125,000 shares of Karyopharm's common stock to Ms. Cheng, with a grant date of June 30, 2021.

• Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

  6/24/2021

  Karyopharm Therapeutics Inc. announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export compound, and for the clinical development of Karyopharm's other programs, including eltanexor.

• Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

  6/9/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association 2021 Virtual Congress taking place June 9-17, 2021.

• Karyopharm Announces Key Changes to Its Commercial Leadership Team

  6/8/2021

  − Sohanya Cheng, Appointed as Head of Sales and Commercial Operations - − Payman Darouian, to Lead Marketing for XPOVIO®.

• Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

  6/3/2021

  -- Three New Strength Tablets Approved by the FDA: 40 mg, 50 mg and 60 mg -- -- New Tablet Strengths Provide Additional Patient Convenience and Dosing Flexibility --

• Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

  6/2/2021

  Karyopharm Therapeutics Inc. announced that on May 26, 2021 the UK's Medicines & Healthcare Products Regulatory Agency granted conditional marketing authorization for NEXPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export medicine

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021

  6/1/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 24,600 shares of Karyopharm's common stock to six newly-hired employees, with a grant date of May 28, 2021.

• Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference

  5/26/2021

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 9:30 a.m. ET. 

• Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

  5/19/2021

   Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4, 2021

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2021

  5/4/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 55,300 shares of Karyopharm's common stock to seven newly-hired employees, with a grant date of April 30, 2021.

• Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

  5/3/2021

  -- Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million -- -- Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021 --

• Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer

  5/3/2021

  -- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership and Global Strategic Experience -- -- Michael G. Kauffman to Remain on Board of Directors and Assume New Role as Senior Clinical Advisor--

• Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021

  4/28/2021

  -- Conference Call Scheduled for Monday, May 3, 2021, at 8:30 a.m. ET --

• Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO®

  4/26/2021

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company's Type II Variation Marketing

• Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology

  4/19/2021

  - Treatment with Selinexor Demonstrated Several Potential Clinical Advantages Compared to Placebo, Including Reduction in Pain, Longer Time to Marked Clinical Deterioration of Pain and Longer Median Time to Next Treatment -

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2021

  4/1/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 150,600 shares of Karyopharm's common stock to 15 newly-hired employees, with a grant date of March 31, 2021.

• Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

  3/29/2021

  Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine